nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Vandetanib—FLT4—polycystic ovary syndrome	0.00599	0.451	CrCbGaD
Bosutinib—Vandetanib—LTK—polycystic ovary syndrome	0.00496	0.374	CrCbGaD
Bosutinib—Chest discomfort—Metformin—polycystic ovary syndrome	0.00309	0.0551	CcSEcCtD
Bosutinib—Renal impairment—Metformin—polycystic ovary syndrome	0.00209	0.0372	CcSEcCtD
Bosutinib—Dehydration—Metformin—polycystic ovary syndrome	0.00185	0.0329	CcSEcCtD
Bosutinib—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00181	0.0323	CcSEcCtD
Bosutinib—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00177	0.0316	CcSEcCtD
Bosutinib—Influenza—Metformin—polycystic ovary syndrome	0.00172	0.0306	CcSEcCtD
Bosutinib—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00164	0.0293	CcSEcCtD
Bosutinib—Neutropenia—Metformin—polycystic ovary syndrome	0.0016	0.0286	CcSEcCtD
Bosutinib—Vandetanib—VEGFA—polycystic ovary syndrome	0.0016	0.12	CrCbGaD
Bosutinib—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00159	0.0284	CcSEcCtD
Bosutinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.00153	0.0273	CcSEcCtD
Bosutinib—Infestation—Metformin—polycystic ovary syndrome	0.00153	0.0273	CcSEcCtD
Bosutinib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00145	0.0258	CcSEcCtD
Bosutinib—Hepatitis—Metformin—polycystic ovary syndrome	0.00137	0.0245	CcSEcCtD
Bosutinib—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00135	0.0241	CcSEcCtD
Bosutinib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00135	0.0241	CcSEcCtD
Bosutinib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00127	0.0227	CcSEcCtD
Bosutinib—Immune system disorder—Metformin—polycystic ovary syndrome	0.00124	0.0221	CcSEcCtD
Bosutinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00124	0.0221	CcSEcCtD
Bosutinib—Malnutrition—Metformin—polycystic ovary syndrome	0.0012	0.0213	CcSEcCtD
Bosutinib—Dysgeusia—Metformin—polycystic ovary syndrome	0.00117	0.0209	CcSEcCtD
Bosutinib—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00111	0.0198	CcSEcCtD
Bosutinib—Malaise—Metformin—polycystic ovary syndrome	0.00108	0.0192	CcSEcCtD
Bosutinib—Chest pain—Metformin—polycystic ovary syndrome	0.00102	0.0181	CcSEcCtD
Bosutinib—Myalgia—Metformin—polycystic ovary syndrome	0.00102	0.0181	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00101	0.018	CcSEcCtD
Bosutinib—Discomfort—Metformin—polycystic ovary syndrome	0.00101	0.0179	CcSEcCtD
Bosutinib—Oedema—Metformin—polycystic ovary syndrome	0.000975	0.0174	CcSEcCtD
Bosutinib—Infection—Metformin—polycystic ovary syndrome	0.000969	0.0173	CcSEcCtD
Bosutinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000957	0.0171	CcSEcCtD
Bosutinib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000955	0.017	CcSEcCtD
Bosutinib—Skin disorder—Metformin—polycystic ovary syndrome	0.000947	0.0169	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000889	0.0158	CcSEcCtD
Bosutinib—Dyspnoea—Metformin—polycystic ovary syndrome	0.00087	0.0155	CcSEcCtD
Bosutinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.000848	0.0151	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000842	0.015	CcSEcCtD
Bosutinib—Fatigue—Metformin—polycystic ovary syndrome	0.000841	0.015	CcSEcCtD
Bosutinib—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000804	0.0143	CcSEcCtD
Bosutinib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000798	0.0142	CcSEcCtD
Bosutinib—Urticaria—Metformin—polycystic ovary syndrome	0.000775	0.0138	CcSEcCtD
Bosutinib—Abdominal pain—Metformin—polycystic ovary syndrome	0.000771	0.0137	CcSEcCtD
Bosutinib—Gefitinib—CYP1A1—polycystic ovary syndrome	0.000732	0.0552	CrCbGaD
Bosutinib—Asthenia—Metformin—polycystic ovary syndrome	0.0007	0.0125	CcSEcCtD
Bosutinib—Pruritus—Metformin—polycystic ovary syndrome	0.00069	0.0123	CcSEcCtD
Bosutinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000667	0.0119	CcSEcCtD
Bosutinib—Dizziness—Metformin—polycystic ovary syndrome	0.000645	0.0115	CcSEcCtD
Bosutinib—Vomiting—Metformin—polycystic ovary syndrome	0.00062	0.0111	CcSEcCtD
Bosutinib—Rash—Metformin—polycystic ovary syndrome	0.000615	0.011	CcSEcCtD
Bosutinib—Dermatitis—Metformin—polycystic ovary syndrome	0.000614	0.011	CcSEcCtD
Bosutinib—Headache—Metformin—polycystic ovary syndrome	0.000611	0.0109	CcSEcCtD
Bosutinib—HCK—adrenal gland—polycystic ovary syndrome	0.000586	0.00146	CbGeAlD
Bosutinib—CLK1—adrenal gland—polycystic ovary syndrome	0.000586	0.00146	CbGeAlD
Bosutinib—MERTK—vagina—polycystic ovary syndrome	0.000584	0.00146	CbGeAlD
Bosutinib—PTK2—uterus—polycystic ovary syndrome	0.000583	0.00145	CbGeAlD
Bosutinib—ABL2—adrenal gland—polycystic ovary syndrome	0.000582	0.00145	CbGeAlD
Bosutinib—MAP3K2—adipose tissue—polycystic ovary syndrome	0.000582	0.00145	CbGeAlD
Bosutinib—ERBB4—endocrine gland—polycystic ovary syndrome	0.000581	0.00145	CbGeAlD
Bosutinib—SLK—endometrium—polycystic ovary syndrome	0.00058	0.00145	CbGeAlD
Bosutinib—Nausea—Metformin—polycystic ovary syndrome	0.000579	0.0103	CcSEcCtD
Bosutinib—MAP3K7—pituitary gland—polycystic ovary syndrome	0.000579	0.00144	CbGeAlD
Bosutinib—MAP4K4—female gonad—polycystic ovary syndrome	0.000577	0.00144	CbGeAlD
Bosutinib—MAP3K7—adipose tissue—polycystic ovary syndrome	0.000577	0.00144	CbGeAlD
Bosutinib—EPHB4—endometrium—polycystic ovary syndrome	0.000576	0.00144	CbGeAlD
Bosutinib—CAMK2G—adrenal gland—polycystic ovary syndrome	0.000575	0.00143	CbGeAlD
Bosutinib—BMP2K—adrenal gland—polycystic ovary syndrome	0.000575	0.00143	CbGeAlD
Bosutinib—ROCK1—endocrine gland—polycystic ovary syndrome	0.000574	0.00143	CbGeAlD
Bosutinib—MAP4K4—vagina—polycystic ovary syndrome	0.000574	0.00143	CbGeAlD
Bosutinib—NUAK2—female gonad—polycystic ovary syndrome	0.000573	0.00143	CbGeAlD
Bosutinib—BCR—female gonad—polycystic ovary syndrome	0.000573	0.00143	CbGeAlD
Bosutinib—PTK2—pituitary gland—polycystic ovary syndrome	0.000573	0.00143	CbGeAlD
Bosutinib—TBK1—pituitary gland—polycystic ovary syndrome	0.000573	0.00143	CbGeAlD
Bosutinib—PTK2—adipose tissue—polycystic ovary syndrome	0.00057	0.00142	CbGeAlD
Bosutinib—TBK1—adipose tissue—polycystic ovary syndrome	0.00057	0.00142	CbGeAlD
Bosutinib—LRRK2—adrenal gland—polycystic ovary syndrome	0.00057	0.00142	CbGeAlD
Bosutinib—YES1—adrenal cortex—polycystic ovary syndrome	0.00057	0.00142	CbGeAlD
Bosutinib—BCR—vagina—polycystic ovary syndrome	0.000569	0.00142	CbGeAlD
Bosutinib—NUAK2—vagina—polycystic ovary syndrome	0.000569	0.00142	CbGeAlD
Bosutinib—MAP3K12—female gonad—polycystic ovary syndrome	0.000569	0.00142	CbGeAlD
Bosutinib—EGFR—adrenal gland—polycystic ovary syndrome	0.000568	0.00142	CbGeAlD
Bosutinib—MAP3K12—vagina—polycystic ovary syndrome	0.000565	0.00141	CbGeAlD
Bosutinib—EPHA2—endometrium—polycystic ovary syndrome	0.000565	0.00141	CbGeAlD
Bosutinib—FYN—endometrium—polycystic ovary syndrome	0.000564	0.00141	CbGeAlD
Bosutinib—TAOK3—adrenal cortex—polycystic ovary syndrome	0.000563	0.0014	CbGeAlD
Bosutinib—IRAK1—adipose tissue—polycystic ovary syndrome	0.000559	0.00139	CbGeAlD
Bosutinib—LCK—uterus—polycystic ovary syndrome	0.000558	0.00139	CbGeAlD
Bosutinib—BMPR2—endocrine gland—polycystic ovary syndrome	0.000557	0.00139	CbGeAlD
Bosutinib—MAP2K1—female gonad—polycystic ovary syndrome	0.000557	0.00139	CbGeAlD
Bosutinib—STK35—female gonad—polycystic ovary syndrome	0.000557	0.00139	CbGeAlD
Bosutinib—PTK2B—adrenal gland—polycystic ovary syndrome	0.000556	0.00139	CbGeAlD
Bosutinib—AXL—uterus—polycystic ovary syndrome	0.000555	0.00139	CbGeAlD
Bosutinib—STK35—vagina—polycystic ovary syndrome	0.000554	0.00138	CbGeAlD
Bosutinib—CSK—female gonad—polycystic ovary syndrome	0.000554	0.00138	CbGeAlD
Bosutinib—STK36—endocrine gland—polycystic ovary syndrome	0.000553	0.00138	CbGeAlD
Bosutinib—MAP4K5—endometrium—polycystic ovary syndrome	0.000551	0.00137	CbGeAlD
Bosutinib—MAP3K3—endometrium—polycystic ovary syndrome	0.000551	0.00137	CbGeAlD
Bosutinib—RPS6KB1—pituitary gland—polycystic ovary syndrome	0.000551	0.00137	CbGeAlD
Bosutinib—CSK—vagina—polycystic ovary syndrome	0.00055	0.00137	CbGeAlD
Bosutinib—CSNK1A1—female gonad—polycystic ovary syndrome	0.00055	0.00137	CbGeAlD
Bosutinib—RPS6KB1—adipose tissue—polycystic ovary syndrome	0.000549	0.00137	CbGeAlD
Bosutinib—FGR—pituitary gland—polycystic ovary syndrome	0.000548	0.00137	CbGeAlD
Bosutinib—MERTK—endocrine gland—polycystic ovary syndrome	0.000547	0.00136	CbGeAlD
Bosutinib—CSNK1A1—vagina—polycystic ovary syndrome	0.000547	0.00136	CbGeAlD
Bosutinib—CSNK1E—adrenal gland—polycystic ovary syndrome	0.000547	0.00136	CbGeAlD
Bosutinib—HCK—female gonad—polycystic ovary syndrome	0.000547	0.00136	CbGeAlD
Bosutinib—CLK1—female gonad—polycystic ovary syndrome	0.000547	0.00136	CbGeAlD
Bosutinib—AXL—pituitary gland—polycystic ovary syndrome	0.000545	0.00136	CbGeAlD
Bosutinib—FGR—adipose tissue—polycystic ovary syndrome	0.000545	0.00136	CbGeAlD
Bosutinib—LCK—adipose tissue—polycystic ovary syndrome	0.000545	0.00136	CbGeAlD
Bosutinib—HCK—vagina—polycystic ovary syndrome	0.000543	0.00135	CbGeAlD
Bosutinib—CLK1—vagina—polycystic ovary syndrome	0.000543	0.00135	CbGeAlD
Bosutinib—AXL—adipose tissue—polycystic ovary syndrome	0.000543	0.00135	CbGeAlD
Bosutinib—ABL2—female gonad—polycystic ovary syndrome	0.000543	0.00135	CbGeAlD
Bosutinib—ABL2—vagina—polycystic ovary syndrome	0.00054	0.00135	CbGeAlD
Bosutinib—SIK1—adrenal gland—polycystic ovary syndrome	0.000538	0.00134	CbGeAlD
Bosutinib—IRAK4—adrenal gland—polycystic ovary syndrome	0.000538	0.00134	CbGeAlD
Bosutinib—MAP4K4—endocrine gland—polycystic ovary syndrome	0.000537	0.00134	CbGeAlD
Bosutinib—CAMK2G—female gonad—polycystic ovary syndrome	0.000536	0.00134	CbGeAlD
Bosutinib—BMP2K—female gonad—polycystic ovary syndrome	0.000536	0.00134	CbGeAlD
Bosutinib—SLK—uterus—polycystic ovary syndrome	0.000535	0.00133	CbGeAlD
Bosutinib—BMP2K—vagina—polycystic ovary syndrome	0.000533	0.00133	CbGeAlD
Bosutinib—CAMK2G—vagina—polycystic ovary syndrome	0.000533	0.00133	CbGeAlD
Bosutinib—PDGFRB—embryo—polycystic ovary syndrome	0.000533	0.00133	CbGeAlD
Bosutinib—BCR—endocrine gland—polycystic ovary syndrome	0.000533	0.00133	CbGeAlD
Bosutinib—EPHA4—adrenal gland—polycystic ovary syndrome	0.000533	0.00133	CbGeAlD
Bosutinib—LRRK2—female gonad—polycystic ovary syndrome	0.000532	0.00133	CbGeAlD
Bosutinib—EPHB4—uterus—polycystic ovary syndrome	0.000531	0.00132	CbGeAlD
Bosutinib—EGFR—female gonad—polycystic ovary syndrome	0.00053	0.00132	CbGeAlD
Bosutinib—MAP3K12—endocrine gland—polycystic ovary syndrome	0.000529	0.00132	CbGeAlD
Bosutinib—LRRK2—vagina—polycystic ovary syndrome	0.000528	0.00132	CbGeAlD
Bosutinib—MAP2K2—adrenal gland—polycystic ovary syndrome	0.000526	0.00131	CbGeAlD
Bosutinib—ULK3—adrenal gland—polycystic ovary syndrome	0.000526	0.00131	CbGeAlD
Bosutinib—SLK—pituitary gland—polycystic ovary syndrome	0.000525	0.00131	CbGeAlD
Bosutinib—SLK—adipose tissue—polycystic ovary syndrome	0.000523	0.0013	CbGeAlD
Bosutinib—MAP3K2—adrenal gland—polycystic ovary syndrome	0.000522	0.0013	CbGeAlD
Bosutinib—EPHB4—pituitary gland—polycystic ovary syndrome	0.000521	0.0013	CbGeAlD
Bosutinib—FYN—uterus—polycystic ovary syndrome	0.00052	0.0013	CbGeAlD
Bosutinib—EPHB4—adipose tissue—polycystic ovary syndrome	0.000519	0.00129	CbGeAlD
Bosutinib—MAP2K1—endocrine gland—polycystic ovary syndrome	0.000518	0.00129	CbGeAlD
Bosutinib—STK35—endocrine gland—polycystic ovary syndrome	0.000518	0.00129	CbGeAlD
Bosutinib—PTK2B—female gonad—polycystic ovary syndrome	0.000518	0.00129	CbGeAlD
Bosutinib—MAP3K7—adrenal gland—polycystic ovary syndrome	0.000518	0.00129	CbGeAlD
Bosutinib—PTK2B—vagina—polycystic ovary syndrome	0.000515	0.00128	CbGeAlD
Bosutinib—CSK—endocrine gland—polycystic ovary syndrome	0.000515	0.00128	CbGeAlD
Bosutinib—TBK1—adrenal gland—polycystic ovary syndrome	0.000512	0.00128	CbGeAlD
Bosutinib—PTK2—adrenal gland—polycystic ovary syndrome	0.000512	0.00128	CbGeAlD
Bosutinib—CSNK1A1—endocrine gland—polycystic ovary syndrome	0.000512	0.00128	CbGeAlD
Bosutinib—EPHA2—pituitary gland—polycystic ovary syndrome	0.000511	0.00128	CbGeAlD
Bosutinib—FYN—pituitary gland—polycystic ovary syndrome	0.00051	0.00127	CbGeAlD
Bosutinib—CSNK1E—female gonad—polycystic ovary syndrome	0.00051	0.00127	CbGeAlD
Bosutinib—EPHA2—adipose tissue—polycystic ovary syndrome	0.000509	0.00127	CbGeAlD
Bosutinib—YES1—endometrium—polycystic ovary syndrome	0.000509	0.00127	CbGeAlD
Bosutinib—FYN—adipose tissue—polycystic ovary syndrome	0.000508	0.00127	CbGeAlD
Bosutinib—CLK1—endocrine gland—polycystic ovary syndrome	0.000508	0.00127	CbGeAlD
Bosutinib—HCK—endocrine gland—polycystic ovary syndrome	0.000508	0.00127	CbGeAlD
Bosutinib—MAP4K5—uterus—polycystic ovary syndrome	0.000508	0.00127	CbGeAlD
Bosutinib—CSNK1E—vagina—polycystic ovary syndrome	0.000507	0.00126	CbGeAlD
Bosutinib—MAP2K5—adrenal cortex—polycystic ovary syndrome	0.000505	0.00126	CbGeAlD
Bosutinib—TAOK3—endometrium—polycystic ovary syndrome	0.000503	0.00125	CbGeAlD
Bosutinib—SIK1—female gonad—polycystic ovary syndrome	0.000502	0.00125	CbGeAlD
Bosutinib—IRAK4—female gonad—polycystic ovary syndrome	0.000502	0.00125	CbGeAlD
Bosutinib—IRAK1—adrenal gland—polycystic ovary syndrome	0.000502	0.00125	CbGeAlD
Bosutinib—CAMK2G—endocrine gland—polycystic ovary syndrome	0.000499	0.00124	CbGeAlD
Bosutinib—BMP2K—endocrine gland—polycystic ovary syndrome	0.000499	0.00124	CbGeAlD
Bosutinib—MAP4K5—pituitary gland—polycystic ovary syndrome	0.000499	0.00124	CbGeAlD
Bosutinib—MAP3K3—pituitary gland—polycystic ovary syndrome	0.000499	0.00124	CbGeAlD
Bosutinib—IRAK4—vagina—polycystic ovary syndrome	0.000499	0.00124	CbGeAlD
Bosutinib—MAP4K5—adipose tissue—polycystic ovary syndrome	0.000497	0.00124	CbGeAlD
Bosutinib—MAP3K3—adipose tissue—polycystic ovary syndrome	0.000497	0.00124	CbGeAlD
Bosutinib—EPHA4—female gonad—polycystic ovary syndrome	0.000497	0.00124	CbGeAlD
Bosutinib—LRRK2—endocrine gland—polycystic ovary syndrome	0.000494	0.00123	CbGeAlD
Bosutinib—EPHA4—vagina—polycystic ovary syndrome	0.000494	0.00123	CbGeAlD
Bosutinib—CSF1R—adrenal cortex—polycystic ovary syndrome	0.000492	0.00123	CbGeAlD
Bosutinib—RPS6KB1—adrenal gland—polycystic ovary syndrome	0.000492	0.00123	CbGeAlD
Bosutinib—ERBB3—female gonad—polycystic ovary syndrome	0.000492	0.00123	CbGeAlD
Bosutinib—MAP2K2—female gonad—polycystic ovary syndrome	0.000491	0.00122	CbGeAlD
Bosutinib—ULK3—female gonad—polycystic ovary syndrome	0.000491	0.00122	CbGeAlD
Bosutinib—LCK—adrenal gland—polycystic ovary syndrome	0.000489	0.00122	CbGeAlD
Bosutinib—FGR—adrenal gland—polycystic ovary syndrome	0.000489	0.00122	CbGeAlD
Bosutinib—ULK3—vagina—polycystic ovary syndrome	0.000488	0.00122	CbGeAlD
Bosutinib—AXL—adrenal gland—polycystic ovary syndrome	0.000487	0.00122	CbGeAlD
Bosutinib—MAP3K2—female gonad—polycystic ovary syndrome	0.000487	0.00121	CbGeAlD
Bosutinib—MAP3K7—female gonad—polycystic ovary syndrome	0.000483	0.0012	CbGeAlD
Bosutinib—PTK2B—endocrine gland—polycystic ovary syndrome	0.000482	0.0012	CbGeAlD
Bosutinib—MAP3K7—vagina—polycystic ovary syndrome	0.00048	0.0012	CbGeAlD
Bosutinib—TBK1—female gonad—polycystic ovary syndrome	0.000477	0.00119	CbGeAlD
Bosutinib—PTK2—female gonad—polycystic ovary syndrome	0.000477	0.00119	CbGeAlD
Bosutinib—ABL1—embryo—polycystic ovary syndrome	0.000475	0.00118	CbGeAlD
Bosutinib—TBK1—vagina—polycystic ovary syndrome	0.000474	0.00118	CbGeAlD
Bosutinib—PTK2—vagina—polycystic ovary syndrome	0.000474	0.00118	CbGeAlD
Bosutinib—CSNK1E—endocrine gland—polycystic ovary syndrome	0.000474	0.00118	CbGeAlD
Bosutinib—YES1—uterus—polycystic ovary syndrome	0.000469	0.00117	CbGeAlD
Bosutinib—SLK—adrenal gland—polycystic ovary syndrome	0.000469	0.00117	CbGeAlD
Bosutinib—IRAK1—female gonad—polycystic ovary syndrome	0.000468	0.00117	CbGeAlD
Bosutinib—SIK1—endocrine gland—polycystic ovary syndrome	0.000467	0.00116	CbGeAlD
Bosutinib—EPHB4—adrenal gland—polycystic ovary syndrome	0.000466	0.00116	CbGeAlD
Bosutinib—STK10—uterus—polycystic ovary syndrome	0.000465	0.00116	CbGeAlD
Bosutinib—TAOK3—uterus—polycystic ovary syndrome	0.000463	0.00116	CbGeAlD
Bosutinib—EPHA4—endocrine gland—polycystic ovary syndrome	0.000462	0.00115	CbGeAlD
Bosutinib—YES1—pituitary gland—polycystic ovary syndrome	0.000461	0.00115	CbGeAlD
Bosutinib—RPS6KB1—female gonad—polycystic ovary syndrome	0.000459	0.00114	CbGeAlD
Bosutinib—YES1—adipose tissue—polycystic ovary syndrome	0.000459	0.00114	CbGeAlD
Bosutinib—ERBB3—endocrine gland—polycystic ovary syndrome	0.000457	0.00114	CbGeAlD
Bosutinib—EPHA2—adrenal gland—polycystic ovary syndrome	0.000457	0.00114	CbGeAlD
Bosutinib—MAP2K2—endocrine gland—polycystic ovary syndrome	0.000456	0.00114	CbGeAlD
Bosutinib—ULK3—endocrine gland—polycystic ovary syndrome	0.000456	0.00114	CbGeAlD
Bosutinib—RPS6KB1—vagina—polycystic ovary syndrome	0.000456	0.00114	CbGeAlD
Bosutinib—LCK—female gonad—polycystic ovary syndrome	0.000456	0.00114	CbGeAlD
Bosutinib—FGR—female gonad—polycystic ovary syndrome	0.000456	0.00114	CbGeAlD
Bosutinib—FYN—adrenal gland—polycystic ovary syndrome	0.000456	0.00114	CbGeAlD
Bosutinib—TAOK3—pituitary gland—polycystic ovary syndrome	0.000455	0.00113	CbGeAlD
Bosutinib—STK10—adipose tissue—polycystic ovary syndrome	0.000455	0.00113	CbGeAlD
Bosutinib—AXL—female gonad—polycystic ovary syndrome	0.000454	0.00113	CbGeAlD
Bosutinib—LCK—vagina—polycystic ovary syndrome	0.000453	0.00113	CbGeAlD
Bosutinib—FGR—vagina—polycystic ovary syndrome	0.000453	0.00113	CbGeAlD
Bosutinib—MAP3K2—endocrine gland—polycystic ovary syndrome	0.000453	0.00113	CbGeAlD
Bosutinib—TAOK3—adipose tissue—polycystic ovary syndrome	0.000453	0.00113	CbGeAlD
Bosutinib—AXL—vagina—polycystic ovary syndrome	0.000452	0.00113	CbGeAlD
Bosutinib—MAP2K5—endometrium—polycystic ovary syndrome	0.000451	0.00112	CbGeAlD
Bosutinib—MAP3K3—adrenal gland—polycystic ovary syndrome	0.000446	0.00111	CbGeAlD
Bosutinib—MAP4K5—adrenal gland—polycystic ovary syndrome	0.000446	0.00111	CbGeAlD
Bosutinib—PTK2—endocrine gland—polycystic ovary syndrome	0.000444	0.00111	CbGeAlD
Bosutinib—TBK1—endocrine gland—polycystic ovary syndrome	0.000444	0.00111	CbGeAlD
Bosutinib—SRC—adipose tissue—polycystic ovary syndrome	0.000441	0.0011	CbGeAlD
Bosutinib—CSF1R—endometrium—polycystic ovary syndrome	0.00044	0.0011	CbGeAlD
Bosutinib—SLK—female gonad—polycystic ovary syndrome	0.000437	0.00109	CbGeAlD
Bosutinib—PDGFRB—adrenal cortex—polycystic ovary syndrome	0.000437	0.00109	CbGeAlD
Bosutinib—SLK—vagina—polycystic ovary syndrome	0.000435	0.00108	CbGeAlD
Bosutinib—EPHB4—female gonad—polycystic ovary syndrome	0.000434	0.00108	CbGeAlD
Bosutinib—EPHB4—vagina—polycystic ovary syndrome	0.000432	0.00108	CbGeAlD
Bosutinib—RPS6KB1—endocrine gland—polycystic ovary syndrome	0.000427	0.00106	CbGeAlD
Bosutinib—EPHA2—female gonad—polycystic ovary syndrome	0.000426	0.00106	CbGeAlD
Bosutinib—FYN—female gonad—polycystic ovary syndrome	0.000425	0.00106	CbGeAlD
Bosutinib—FGR—endocrine gland—polycystic ovary syndrome	0.000424	0.00106	CbGeAlD
Bosutinib—EPHA2—vagina—polycystic ovary syndrome	0.000423	0.00106	CbGeAlD
Bosutinib—FYN—vagina—polycystic ovary syndrome	0.000423	0.00105	CbGeAlD
Bosutinib—AXL—endocrine gland—polycystic ovary syndrome	0.000422	0.00105	CbGeAlD
Bosutinib—MAP3K3—female gonad—polycystic ovary syndrome	0.000415	0.00104	CbGeAlD
Bosutinib—MAP4K5—female gonad—polycystic ovary syndrome	0.000415	0.00104	CbGeAlD
Bosutinib—MAP3K3—vagina—polycystic ovary syndrome	0.000413	0.00103	CbGeAlD
Bosutinib—MAP4K5—vagina—polycystic ovary syndrome	0.000413	0.00103	CbGeAlD
Bosutinib—YES1—adrenal gland—polycystic ovary syndrome	0.000412	0.00103	CbGeAlD
Bosutinib—STK10—adrenal gland—polycystic ovary syndrome	0.000408	0.00102	CbGeAlD
Bosutinib—MAP2K5—pituitary gland—polycystic ovary syndrome	0.000408	0.00102	CbGeAlD
Bosutinib—TAOK3—adrenal gland—polycystic ovary syndrome	0.000406	0.00101	CbGeAlD
Bosutinib—MAP2K5—adipose tissue—polycystic ovary syndrome	0.000406	0.00101	CbGeAlD
Bosutinib—CSF1R—uterus—polycystic ovary syndrome	0.000405	0.00101	CbGeAlD
Bosutinib—EPHB4—endocrine gland—polycystic ovary syndrome	0.000404	0.00101	CbGeAlD
Bosutinib—CSF1R—pituitary gland—polycystic ovary syndrome	0.000398	0.000992	CbGeAlD
Bosutinib—CSF1R—adipose tissue—polycystic ovary syndrome	0.000396	0.000988	CbGeAlD
Bosutinib—EPHA2—endocrine gland—polycystic ovary syndrome	0.000396	0.000988	CbGeAlD
Bosutinib—SRC—adrenal gland—polycystic ovary syndrome	0.000396	0.000987	CbGeAlD
Bosutinib—FYN—endocrine gland—polycystic ovary syndrome	0.000395	0.000986	CbGeAlD
Bosutinib—PDGFRB—endometrium—polycystic ovary syndrome	0.00039	0.000973	CbGeAlD
Bosutinib—ABL1—adrenal cortex—polycystic ovary syndrome	0.000389	0.000971	CbGeAlD
Bosutinib—MAP3K3—endocrine gland—polycystic ovary syndrome	0.000386	0.000964	CbGeAlD
Bosutinib—MAP4K5—endocrine gland—polycystic ovary syndrome	0.000386	0.000964	CbGeAlD
Bosutinib—YES1—female gonad—polycystic ovary syndrome	0.000384	0.000957	CbGeAlD
Bosutinib—YES1—vagina—polycystic ovary syndrome	0.000381	0.000951	CbGeAlD
Bosutinib—STK10—female gonad—polycystic ovary syndrome	0.00038	0.000948	CbGeAlD
Bosutinib—TAOK3—female gonad—polycystic ovary syndrome	0.000379	0.000945	CbGeAlD
Bosutinib—STK10—vagina—polycystic ovary syndrome	0.000378	0.000943	CbGeAlD
Bosutinib—TAOK3—vagina—polycystic ovary syndrome	0.000377	0.000939	CbGeAlD
Bosutinib—SRC—female gonad—polycystic ovary syndrome	0.000369	0.000921	CbGeAlD
Bosutinib—MAP2K5—adrenal gland—polycystic ovary syndrome	0.000364	0.000908	CbGeAlD
Bosutinib—PDGFRB—uterus—polycystic ovary syndrome	0.000359	0.000896	CbGeAlD
Bosutinib—YES1—endocrine gland—polycystic ovary syndrome	0.000357	0.00089	CbGeAlD
Bosutinib—CSF1R—adrenal gland—polycystic ovary syndrome	0.000355	0.000886	CbGeAlD
Bosutinib—STK10—endocrine gland—polycystic ovary syndrome	0.000354	0.000882	CbGeAlD
Bosutinib—PDGFRB—pituitary gland—polycystic ovary syndrome	0.000353	0.00088	CbGeAlD
Bosutinib—TAOK3—endocrine gland—polycystic ovary syndrome	0.000352	0.000879	CbGeAlD
Bosutinib—PDGFRB—adipose tissue—polycystic ovary syndrome	0.000351	0.000877	CbGeAlD
Bosutinib—ABL1—endometrium—polycystic ovary syndrome	0.000348	0.000867	CbGeAlD
Bosutinib—SRC—endocrine gland—polycystic ovary syndrome	0.000343	0.000856	CbGeAlD
Bosutinib—MAP2K5—female gonad—polycystic ovary syndrome	0.00034	0.000847	CbGeAlD
Bosutinib—MAP2K5—vagina—polycystic ovary syndrome	0.000338	0.000842	CbGeAlD
Bosutinib—CSF1R—female gonad—polycystic ovary syndrome	0.000331	0.000827	CbGeAlD
Bosutinib—CSF1R—vagina—polycystic ovary syndrome	0.000329	0.000822	CbGeAlD
Bosutinib—ABL1—uterus—polycystic ovary syndrome	0.00032	0.000799	CbGeAlD
Bosutinib—MAP2K5—endocrine gland—polycystic ovary syndrome	0.000316	0.000788	CbGeAlD
Bosutinib—PDGFRB—adrenal gland—polycystic ovary syndrome	0.000315	0.000786	CbGeAlD
Bosutinib—ABL1—pituitary gland—polycystic ovary syndrome	0.000315	0.000784	CbGeAlD
Bosutinib—ABL1—adipose tissue—polycystic ovary syndrome	0.000313	0.000781	CbGeAlD
Bosutinib—CSF1R—endocrine gland—polycystic ovary syndrome	0.000308	0.000769	CbGeAlD
Bosutinib—PDGFRB—female gonad—polycystic ovary syndrome	0.000294	0.000733	CbGeAlD
Bosutinib—PDGFRB—vagina—polycystic ovary syndrome	0.000292	0.000729	CbGeAlD
Bosutinib—ABL1—adrenal gland—polycystic ovary syndrome	0.000281	0.000701	CbGeAlD
Bosutinib—PDGFRB—endocrine gland—polycystic ovary syndrome	0.000273	0.000682	CbGeAlD
Bosutinib—ABL1—female gonad—polycystic ovary syndrome	0.000262	0.000653	CbGeAlD
Bosutinib—ABL1—vagina—polycystic ovary syndrome	0.00026	0.000649	CbGeAlD
Bosutinib—ABL1—endocrine gland—polycystic ovary syndrome	0.000244	0.000608	CbGeAlD
Bosutinib—ABCB1—embryo—polycystic ovary syndrome	0.000148	0.000368	CbGeAlD
Bosutinib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000121	0.000302	CbGeAlD
Bosutinib—ABCB1—endometrium—polycystic ovary syndrome	0.000108	0.00027	CbGeAlD
Bosutinib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000107	0.000267	CbGeAlD
Bosutinib—ABCB1—uterus—polycystic ovary syndrome	9.96e-05	0.000248	CbGeAlD
Bosutinib—ABCB1—pituitary gland—polycystic ovary syndrome	9.78e-05	0.000244	CbGeAlD
Bosutinib—ABCB1—adipose tissue—polycystic ovary syndrome	9.74e-05	0.000243	CbGeAlD
Bosutinib—ABCB1—adrenal gland—polycystic ovary syndrome	8.74e-05	0.000218	CbGeAlD
Bosutinib—ABCB1—female gonad—polycystic ovary syndrome	8.15e-05	0.000203	CbGeAlD
Bosutinib—ABCB1—vagina—polycystic ovary syndrome	8.1e-05	0.000202	CbGeAlD
Bosutinib—ABCB1—endocrine gland—polycystic ovary syndrome	7.58e-05	0.000189	CbGeAlD
Bosutinib—ABL1—Developmental Biology—IL6—polycystic ovary syndrome	3.74e-06	7.06e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—BCL2—polycystic ovary syndrome	3.73e-06	7.05e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MTHFR—polycystic ovary syndrome	3.73e-06	7.03e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—BCL2—polycystic ovary syndrome	3.72e-06	7.02e-06	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—IL6—polycystic ovary syndrome	3.72e-06	7.02e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.71e-06	7e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.71e-06	7e-06	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—IL6—polycystic ovary syndrome	3.7e-06	6.99e-06	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—IL6—polycystic ovary syndrome	3.7e-06	6.98e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—SERPINE1—polycystic ovary syndrome	3.69e-06	6.97e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—IL6—polycystic ovary syndrome	3.68e-06	6.95e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—BCL2—polycystic ovary syndrome	3.68e-06	6.94e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—SERPINE1—polycystic ovary syndrome	3.67e-06	6.93e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—POMC—polycystic ovary syndrome	3.66e-06	6.91e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—BCL2—polycystic ovary syndrome	3.66e-06	6.9e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	3.65e-06	6.89e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—INS—polycystic ovary syndrome	3.64e-06	6.87e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT2—polycystic ovary syndrome	3.64e-06	6.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—GNAS—polycystic ovary syndrome	3.63e-06	6.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IRS1—polycystic ovary syndrome	3.63e-06	6.85e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.62e-06	6.84e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	3.6e-06	6.8e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.58e-06	6.76e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—IL6—polycystic ovary syndrome	3.58e-06	6.76e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IRS1—polycystic ovary syndrome	3.58e-06	6.75e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.57e-06	6.74e-06	CbGpPWpGaD
Bosutinib—HCK—Immune System—IL6—polycystic ovary syndrome	3.56e-06	6.71e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NGFR—polycystic ovary syndrome	3.55e-06	6.71e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IRS2—polycystic ovary syndrome	3.54e-06	6.69e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PRL—polycystic ovary syndrome	3.52e-06	6.65e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.52e-06	6.65e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	3.52e-06	6.64e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.52e-06	6.64e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.52e-06	6.64e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT2—polycystic ovary syndrome	3.5e-06	6.62e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—LEP—polycystic ovary syndrome	3.5e-06	6.61e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—GNAS—polycystic ovary syndrome	3.5e-06	6.61e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IRS1—polycystic ovary syndrome	3.5e-06	6.6e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IRS2—polycystic ovary syndrome	3.49e-06	6.6e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—IL6—polycystic ovary syndrome	3.48e-06	6.57e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—INS—polycystic ovary syndrome	3.47e-06	6.56e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—IL6—polycystic ovary syndrome	3.47e-06	6.56e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.46e-06	6.53e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—POMC—polycystic ovary syndrome	3.44e-06	6.5e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	3.44e-06	6.49e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—INS—polycystic ovary syndrome	3.43e-06	6.47e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IRS2—polycystic ovary syndrome	3.42e-06	6.46e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—LEP—polycystic ovary syndrome	3.42e-06	6.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRG1—polycystic ovary syndrome	3.4e-06	6.41e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—IL6—polycystic ovary syndrome	3.39e-06	6.4e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	3.38e-06	6.38e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IRS2—polycystic ovary syndrome	3.37e-06	6.36e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT2—polycystic ovary syndrome	3.36e-06	6.34e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IRS1—polycystic ovary syndrome	3.35e-06	6.33e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.35e-06	6.32e-06	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—IL6—polycystic ovary syndrome	3.35e-06	6.32e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—LEP—polycystic ovary syndrome	3.35e-06	6.32e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—INS—polycystic ovary syndrome	3.35e-06	6.32e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.34e-06	6.31e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.34e-06	6.31e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	3.34e-06	6.3e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.33e-06	6.3e-06	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—IL6—polycystic ovary syndrome	3.32e-06	6.26e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IGF1—polycystic ovary syndrome	3.31e-06	6.25e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT2—polycystic ovary syndrome	3.31e-06	6.25e-06	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—IL6—polycystic ovary syndrome	3.3e-06	6.24e-06	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IL6—polycystic ovary syndrome	3.3e-06	6.23e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—LEP—polycystic ovary syndrome	3.3e-06	6.22e-06	CbGpPWpGaD
Bosutinib—HCK—Disease—IL6—polycystic ovary syndrome	3.28e-06	6.2e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—LEP—polycystic ovary syndrome	3.28e-06	6.19e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRG1—polycystic ovary syndrome	3.27e-06	6.18e-06	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—IL6—polycystic ovary syndrome	3.27e-06	6.17e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—IL6—polycystic ovary syndrome	3.25e-06	6.13e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT2—polycystic ovary syndrome	3.24e-06	6.11e-06	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL6—polycystic ovary syndrome	3.22e-06	6.08e-06	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL6—polycystic ovary syndrome	3.21e-06	6.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—IL6—polycystic ovary syndrome	3.2e-06	6.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—SERPINE1—polycystic ovary syndrome	3.19e-06	6.02e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—BCL2—polycystic ovary syndrome	3.18e-06	6e-06	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IL6—polycystic ovary syndrome	3.16e-06	5.97e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	3.15e-06	5.95e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.15e-06	5.94e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.13e-06	5.91e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.13e-06	5.9e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	3.1e-06	5.86e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT2—polycystic ovary syndrome	3.1e-06	5.86e-06	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IL6—polycystic ovary syndrome	3.1e-06	5.86e-06	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IL6—polycystic ovary syndrome	3.1e-06	5.86e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—GNAS—polycystic ovary syndrome	3.1e-06	5.85e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IRS1—polycystic ovary syndrome	3.09e-06	5.84e-06	CbGpPWpGaD
Bosutinib—ERBB4—Disease—IL6—polycystic ovary syndrome	3.09e-06	5.84e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.09e-06	5.83e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—SERPINE1—polycystic ovary syndrome	3.07e-06	5.8e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	3.06e-06	5.79e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—BCL2—polycystic ovary syndrome	3.06e-06	5.78e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IRS1—polycystic ovary syndrome	3.05e-06	5.76e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—POMC—polycystic ovary syndrome	3.01e-06	5.68e-06	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL6—polycystic ovary syndrome	3e-06	5.65e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—INS—polycystic ovary syndrome	2.99e-06	5.65e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IRS1—polycystic ovary syndrome	2.99e-06	5.64e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.97e-06	5.61e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—INS—polycystic ovary syndrome	2.96e-06	5.59e-06	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL6—polycystic ovary syndrome	2.95e-06	5.57e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.95e-06	5.57e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IRS1—polycystic ovary syndrome	2.94e-06	5.55e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—POMC—polycystic ovary syndrome	2.94e-06	5.55e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.92e-06	5.52e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	2.92e-06	5.52e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—INS—polycystic ovary syndrome	2.92e-06	5.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IRS2—polycystic ovary syndrome	2.91e-06	5.49e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRG1—polycystic ovary syndrome	2.9e-06	5.47e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.9e-06	5.47e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.89e-06	5.46e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—POMC—polycystic ovary syndrome	2.88e-06	5.43e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT2—polycystic ovary syndrome	2.86e-06	5.41e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.86e-06	5.41e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.86e-06	5.41e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—INS—polycystic ovary syndrome	2.86e-06	5.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—LEP—polycystic ovary syndrome	2.85e-06	5.38e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—POMC—polycystic ovary syndrome	2.83e-06	5.34e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IGF1—polycystic ovary syndrome	2.83e-06	5.33e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT2—polycystic ovary syndrome	2.82e-06	5.33e-06	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—polycystic ovary syndrome	2.82e-06	5.33e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—POMC—polycystic ovary syndrome	2.82e-06	5.32e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—INS—polycystic ovary syndrome	2.82e-06	5.32e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IRS2—polycystic ovary syndrome	2.8e-06	5.29e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—INS—polycystic ovary syndrome	2.8e-06	5.29e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IGF1—polycystic ovary syndrome	2.77e-06	5.22e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT2—polycystic ovary syndrome	2.76e-06	5.22e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.76e-06	5.21e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.75e-06	5.19e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—LEP—polycystic ovary syndrome	2.74e-06	5.18e-06	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—polycystic ovary syndrome	2.73e-06	5.15e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—polycystic ovary syndrome	2.73e-06	5.15e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IGF1—polycystic ovary syndrome	2.72e-06	5.14e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—SERPINE1—polycystic ovary syndrome	2.72e-06	5.14e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT2—polycystic ovary syndrome	2.72e-06	5.14e-06	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—polycystic ovary syndrome	2.72e-06	5.13e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—BCL2—polycystic ovary syndrome	2.71e-06	5.12e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.71e-06	5.11e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.71e-06	5.11e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TH—polycystic ovary syndrome	2.69e-06	5.07e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.68e-06	5.07e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	2.67e-06	5.03e-06	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—polycystic ovary syndrome	2.63e-06	4.96e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.63e-06	4.96e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	2.61e-06	4.93e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	2.61e-06	4.92e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—polycystic ovary syndrome	2.59e-06	4.89e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.59e-06	4.88e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.57e-06	4.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IRS1—polycystic ovary syndrome	2.54e-06	4.8e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	2.52e-06	4.76e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—polycystic ovary syndrome	2.51e-06	4.73e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IRS2—polycystic ovary syndrome	2.48e-06	4.69e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—polycystic ovary syndrome	2.46e-06	4.64e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.46e-06	4.64e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	2.46e-06	4.64e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IRS1—polycystic ovary syndrome	2.45e-06	4.62e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—POMC—polycystic ovary syndrome	2.45e-06	4.62e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—INS—polycystic ovary syndrome	2.43e-06	4.59e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—LEP—polycystic ovary syndrome	2.43e-06	4.59e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.42e-06	4.57e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—polycystic ovary syndrome	2.41e-06	4.55e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—POMC—polycystic ovary syndrome	2.36e-06	4.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF1—polycystic ovary syndrome	2.35e-06	4.44e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT2—polycystic ovary syndrome	2.35e-06	4.44e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—INS—polycystic ovary syndrome	2.34e-06	4.43e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	2.32e-06	4.38e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—polycystic ovary syndrome	2.31e-06	4.37e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.3e-06	4.34e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF1—polycystic ovary syndrome	2.27e-06	4.28e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT2—polycystic ovary syndrome	2.27e-06	4.28e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	2.25e-06	4.25e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.23e-06	4.22e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.21e-06	4.18e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	2.19e-06	4.14e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	2.17e-06	4.09e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IRS1—polycystic ovary syndrome	2.17e-06	4.09e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—polycystic ovary syndrome	2.17e-06	4.09e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.16e-06	4.09e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.15e-06	4.06e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—polycystic ovary syndrome	2.13e-06	4.03e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	2.09e-06	3.94e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—POMC—polycystic ovary syndrome	2.09e-06	3.94e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	2.08e-06	3.93e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—INS—polycystic ovary syndrome	2.08e-06	3.92e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.07e-06	3.91e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	2.06e-06	3.88e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—polycystic ovary syndrome	2.06e-06	3.88e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—polycystic ovary syndrome	2.02e-06	3.82e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1—polycystic ovary syndrome	2.01e-06	3.79e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT2—polycystic ovary syndrome	2.01e-06	3.79e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—polycystic ovary syndrome	1.98e-06	3.74e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—polycystic ovary syndrome	1.98e-06	3.74e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	1.98e-06	3.74e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—polycystic ovary syndrome	1.97e-06	3.73e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.94e-06	3.67e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—polycystic ovary syndrome	1.93e-06	3.65e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—polycystic ovary syndrome	1.92e-06	3.63e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.91e-06	3.61e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—polycystic ovary syndrome	1.91e-06	3.6e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.91e-06	3.6e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—polycystic ovary syndrome	1.9e-06	3.59e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—polycystic ovary syndrome	1.89e-06	3.57e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.89e-06	3.57e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—polycystic ovary syndrome	1.87e-06	3.53e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	1.85e-06	3.49e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.85e-06	3.48e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—polycystic ovary syndrome	1.82e-06	3.44e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.81e-06	3.41e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—polycystic ovary syndrome	1.8e-06	3.4e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.78e-06	3.36e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.77e-06	3.34e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—polycystic ovary syndrome	1.76e-06	3.32e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—polycystic ovary syndrome	1.75e-06	3.3e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—polycystic ovary syndrome	1.7e-06	3.21e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—polycystic ovary syndrome	1.68e-06	3.16e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.65e-06	3.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—polycystic ovary syndrome	1.64e-06	3.1e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.61e-06	3.04e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—polycystic ovary syndrome	1.59e-06	3e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—polycystic ovary syndrome	1.58e-06	2.99e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.54e-06	2.9e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—polycystic ovary syndrome	1.52e-06	2.87e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.51e-06	2.86e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.5e-06	2.83e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—polycystic ovary syndrome	1.5e-06	2.83e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.48e-06	2.8e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.48e-06	2.79e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.47e-06	2.77e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—polycystic ovary syndrome	1.46e-06	2.76e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—polycystic ovary syndrome	1.4e-06	2.65e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.35e-06	2.55e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.31e-06	2.48e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—polycystic ovary syndrome	1.31e-06	2.47e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—polycystic ovary syndrome	1.29e-06	2.44e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.29e-06	2.43e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—polycystic ovary syndrome	1.28e-06	2.41e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—polycystic ovary syndrome	1.25e-06	2.36e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—polycystic ovary syndrome	1.23e-06	2.32e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—polycystic ovary syndrome	1.22e-06	2.31e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.22e-06	2.3e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.14e-06	2.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—polycystic ovary syndrome	1.06e-06	2.01e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—polycystic ovary syndrome	1.02e-06	1.93e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	9.22e-07	1.74e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	9.1e-07	1.72e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—polycystic ovary syndrome	9.07e-07	1.71e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	9.05e-07	1.71e-06	CbGpPWpGaD
